Healthcare Industry News: OrbusNeich
News Release - January 21, 2013
OrbusNeich's COMBO Dual Therapy Stent(TM) to Be Featured During AsiaPCR/SingLIVE 2013 SymposiumHONG KONG, Jan. 21, 2013 -- (Healthcare Sales & Marketing Network) -- OrbusNeich ( http://www.OrbusNeich.com ) today announced that it will host a symposium featuring the COMBO Dual Therapy Stent at AsiaPCR/SingLIVE 2013 entitled "A New Dimension to Stent Therapy." The symposium will take place on Thursday, Jan. 24, at 12:15 p.m. SGT in the Grand Ballroom, Level 5, Room 3, at the Marina Bay Sands -- Sands Expo and Convention Centre in Singapore.
The event will be chaired by Dr. Aaron Wong of the National Heart Centre Singapore, and panel members will include Prof. Huay Cheem Tan of the National University Heart Centre, Singapore (NUHCS), Prof. Teguh Santoso of Medistra Hospital, Indonesia, and Dr. Paul Ong of Tan Tock Seng Hospital, Singapore.
-- Introduction -- Dr. Aaron Wong
-- COMBO Dual Therapy Stent: Is there a need? -- Prof. Elena Ladich
-- Assessing the Healing Response with OCT -- Dr. William Wijns
-- Addressing the Unmet Needs of Balancing Bleeding & Ischemic Events? -- Prof. Roxana Mehran
-- Take-Home Message -- Dr. Aaron Wong
"With the COMBO Dual Therapy Stent, we are most excited about the possibility of achieving better outcomes with less dependence on prolonged dual antiplatelet therapy," said Prof. Mehran of the Mount Sinai Medical Center in New York. "The COMBO Stent, which combines the anti-restenotic property of a drug eluting stent with a pro-healing endothelial progenitor cell capture technology, may help interventional cardiologists to better balance the risk of bleeding and ischemic events."
Dr. William Wijns of the Cardiovascular Center, Aalst, Belgium, added, "Delayed arterial healing following the placement of a drug eluting stent remains a risk factor for major complications such as thrombotic events. The COMBO Dual Therapy Stent is designed to control neointimal growth while accelerating the natural healing process. Optical coherence tomography (OCT) is an imaging technology that may help us to better understand arterial healing."
About the COMBO Dual Therapy Stent
The COMBO Dual Therapy Stent is the first dual therapy stent to both accelerate endothelial coverage and control neo-intimal proliferation through the combination of the proven pro-healing technology with an abluminal sirolimus drug elution delivered from a biodegradable polymer that achieves full and complete dissipation by 90 days.
OrbusNeich's patented EPC capture technology promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that captures EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.
OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous(TM) Stent, and the world's first dual therapy stent, the COMBO Dual Therapy Stent. Other products include stents and balloons marketed under the names of Azule(TM), R stent, Scoreflex(TM), Sapphire(TM), Sapphire II and Sapphire NC. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.
Follow OrbusNeich on Twitter at www.twitter.com/OrbusNeich, and learn more about the company and its innovative technology on OrbusNeich's YouTube Channel: http://www.youtube.com/user/OrbusNeichMedia.
Note: OrbusNeich's stents will be on display at booth #5 at AsiaPCR/SingLIVE 2013.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.